.jpeg)
2026-04-03 06:57:16
Deucravacitinib (brand name Sotyktu, Chinese trade name Songdiduo) is a next-generation, oral, highly selective TYK2 inhibitor developed for the pathological mechanism of psoriasis. Approved in multiple countries and regions worldwide for the systemic treatment of adults with moderate-to-severe plaque psoriasis, it precisely modulates inflammatory pathways to improve skin lesions, with the advantages of rapid onset, durable long-term efficacy, and convenient oral administration, providing a non-injectable, non-biologic treatment option for patients with psoriasis.
2026-03-18 05:32:12
Apremilast is an oral small-molecule PDE4 inhibitor used to treat psoriasis, psoriatic arthritis and Behcet's disease. This article explains its mechanism, efficacy and safety.
2026-03-12 03:31:19
Remibrutinib (brand name Ruipoduo) is a highly selective Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria. Clinical studies show good safety and tolerability, with common side effects including headache and gastrointestinal reactions. Infection prevention, hematological monitoring, and long-term follow-up are key.
2025-10-19 11:44:20
